DMSI Dermisonics Inc New (CE)

Dermisonics, Inc. (OTCBB:DMSI), a medical device company with its focus on the development of an ultrasonically assisted transdermal drug-delivery technology, announced today that its has formed a sales and marketing alliance with PharmaVentures Ltd (Oxford, UK) to promote its groundbreaking U-Strip transdermal drug-delivery device. PharmaVentures, http://www.pharmaventures.com, is a specialist pharmaceutical consultancy serving the business needs of both emerging and established healthcare companies. Specifically, Dermisonics is offering pharmaceutical companies a new U-Strip Drug Screening Program whereby select compounds can be screened for their potential to be delivered via the U-Strip Ultrasonic Drug Delivery System. These screening studies include three major investigations: -0- *T 1) Exposure of the compound to ultrasonic energy to determine if there are any degradation effects caused by the ultrasound. 2) Patch release trials to determine loading factors upon select patch designs, and the dose released from the patch in response to ultrasonic stimulus. 3) Skin permeation trials whereby the drug-loaded patch is applied to human whole skin to determine the dose delivery factors. *T PharmaVentures and Dermisonics will seek to secure screening contracts over the next several months from large multinational pharmaceutical concerns. The purpose of the screening process is to identify the next generation of drug candidates for the Company's ultrasonic drug delivery system. Management hopes the program will lead to other strategic partnerships as viable products emerge from the screening program. For pharmaceutical sponsors, this service enables them to speed drug discovery by focusing upon an alternative and novel delivery method, allowing them to recapture their investment in development stage compounds that have not proven effective with traditional delivery methods. About Dermisonics, Inc. Dermisonics Inc. is a medical device company that is focused on the ongoing development, testing and eventual commercialization of a transdermal patch that has been designed to facilitate the efficient and needle-free delivery of heavy molecular drugs into the system. The U-Strip(TM) is a drug delivery system incorporating a transdermal patch in combination with microelectronics and ultrasonic technology. Tests have shown that this system facilitates the transdermal delivery of Insulin as well as potentially at least 175 other existing drugs that at present cannot be effectively delivered through the pores of the skin using conventionally available transdermal technology due to their large molecular size. About PharmaVentures Ltd. PharmaVentures is a leading results driven organisation assisting pharmaceutical and biotechnology companies worldwide in all aspects of deal making. Comprising two specialist areas - PharmaVentures Consulting and PharmaVentures Intelligence, we work with our clients to drive greater value from their deals. Based in Oxford, UK the company employs over 30 people and has offices in the USA. Legal Notice Regarding Forward-Looking Statements This release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934 that are based upon current expectations or beliefs, as well as a number of assumptions about future events. Although the Company believes that the expectations reflected in the forward-looking statements and the assumptions upon which they are based are reasonable, it can give no assurance that such expectations and assumptions will prove to have been correct. The reader is cautioned not to put undue reliance on these forward-looking statements, as these statements are subject to numerous factors and uncertainties, including but not limited to adverse economic conditions, intense competition, lack of meaningful research results, entry of new competitors and products, adverse federal, state and local government regulation, inadequate capital, unexpected costs and operating deficits, increases in general and administrative costs, termination of contracts or agreements, technological obsolescence of the Company's products, technical problems with the Company's research and products, price increases for supplies and components, litigation and administrative proceedings involving the Company, the possible acquisition of new businesses or that result in operating losses or that do not perform as anticipated, unanticipated losses, the possible fluctuation and volatility of the Company's operating results, financial condition and stock price, losses incurred in litigating and settling cases, dilution in the Company's ownership of its business, adverse publicity and news coverage, inability to carry out research, development and commercialization plans, loss or retirement of key executives and research scientists, changes in interest rates, inflationary factors, and other specific risks. In addition, other factors that could cause actual results to differ materially are discussed in the Company's most recent Form 10-QSB and Form 10-KSB filings with the Securities and Exchange Commission.